ALX Oncology Secures $140M in Highly Dilutive Offering, Halts US Registrational Path for Lead Gastric Cancer Program

summarizeSummary

ALX Oncology completed a highly dilutive $140.4 million equity offering to extend its cash runway through 1H 2028, while simultaneously announcing it will not pursue U.S. regulatory approval for its lead gastric cancer program, ASPEN-06, and will seek partnerships instead.

check_boxKey Events

• Completed Highly Dilutive Equity Offering

  In February 2026, the company completed a registered offering, raising $140.4 million in net proceeds through the issuance of 76,979,112 common shares and 18,574,120 pre-funded warrants. This offering represents a potential dilution of approximately 72.6% to existing shareholders.

• Extended Cash Runway

  The proceeds from the February 2026 offering are expected to fund operations through the first half of 2028, providing crucial liquidity for a clinical-stage biotech.

• Halted US Registrational Path for ASPEN-06

  The company announced it will not pursue a U.S. registrational path for evorpacept in HER2-positive gastric/GEJ cancer (ASPEN-06 trial) following FDA guidance, and will instead explore development partnerships for the program.

• ALX2004 ADC Program Progresses in Phase 1

  The ALX2004 EGFR-targeted ADC program is advancing in its Phase 1 clinical trial, with the first patient dosed in August 2025 and enrollment in the third dose cohort initiated in January 2026, showing no dose-limiting toxicities in initial cohorts.

auto_awesomeAnalysis

ALX Oncology's annual report reveals a critical financial and pipeline update. The company recently completed a registered offering in February 2026, raising $140.4 million in net proceeds. This substantial capital infusion, which included the issuance of 76,979,112 common shares and 18,574,120 pre-funded warrants, is highly dilutive to existing shareholders, representing a potential dilution of approximately 72.6% based on shares outstanding as of March 2, 2026. While this financing extends the company's cash runway through the first half of 2028, it comes at a significant cost. Concurrently, the company announced a major setback for its lead product candidate, evorpacept, in gastric/GEJ cancer (ASPEN-06 trial), deciding not to pursue a U.S. registrational path and instead seeking development partnerships. This negative pipeline news is partially offset by positive early progress for ALX2004, an EGFR-targeted ADC, which is advancing in Phase 1 with no dose-limiting toxicities observed. The company also reported a reduced net loss for 2025 compared to prior years, indicating some operational efficiency, but the overall impact of the high dilution and pipeline re-prioritization is significant.